Safe Constipation Medications in Pregnancy
Start with dietary fiber (30 g/day), then use polyethylene glycol or lactulose as first-line pharmacologic therapy—both are safe and effective throughout pregnancy. 1
Stepwise Treatment Algorithm
First-Line: Non-Pharmacologic Measures
- Increase dietary fiber to 30 g/day from fruits, vegetables, whole grains, and legumes
- Ensure adequate fluid intake, particularly water, to soften stools
- Encourage adequate time for bowel movements without straining
These lifestyle modifications address the underlying hormonal and physiological changes (elevated progesterone slowing GI motility) that cause constipation in 20-40% of pregnant women 1.
Second-Line: Bulk-Forming Agents
Psyllium husk or methylcellulose are safe throughout pregnancy due to lack of systemic absorption 1. Soluble fiber like psyllium is superior to insoluble fiber because it improves both stool viscosity and transit time, not just bulk.
Common pitfall: Excessive fiber can cause maternal bloating—titrate dose based on tolerance.
Third-Line: Osmotic Laxatives (Primary Pharmacologic Treatment)
Polyethylene glycol (PEG) 17 g daily and lactulose 15 g daily are both safe and effective 1. The 2024 AGA guideline explicitly recommends these as treatment options for pregnancy-related constipation.
Evidence comparison: A 2024 RCT of 247 pregnant women found both PEG and lactulose achieved similar rates of complete spontaneous bowel movements (86.3% vs 82.9%), but PEG caused less diarrhea and loose stools 2. A 2020 RCT showed PEG had faster onset of action, achieving therapeutic effect by week 2 versus week 3 for lactulose 3.
Practical considerations:
- Lactulose is the only osmotic agent specifically studied in pregnancy 4, making it a conservative first choice
- PEG may be preferred if faster relief is needed or if lactulose causes intolerable bloating and flatulence 2, 3
- Both can cause maternal bloating—counsel patients accordingly 1
Magnesium oxide: Use with caution—safe in pregnancy but requires monitoring in patients with renal insufficiency 4
Fourth-Line: Stimulant Laxatives (Rescue Therapy Only)
Stimulant laxatives should be avoided as routine therapy because safety data are conflicting 1. This is a strong recommendation from the 2024 AGA pregnancy guideline.
However, bisacodyl and senna may be used for short-term rescue therapy when osmotic laxatives fail 4. One expert review suggests bisacodyl and sodium picosulfate can be considered in the second and third trimesters if first-line therapies are ineffective 5.
Critical caveat: Stimulant laxatives can cause tenesmus (painful straining), which theoretically increases preterm birth risk—this concern is particularly relevant in the second and third trimesters 5.
Medications to Avoid
Do NOT use:
- Newer prescription agents (linaclotide, plecanatide, prucalopride, lubiprostone): No safety data in pregnancy 4
- Mineral oil: Potential interference with fat-soluble vitamin absorption
Management of Associated Hemorrhoids
Hydrocortisone foam is safe in the third trimester—a prospective study of 204 patients showed no adverse events compared to placebo 1.
Key Clinical Pearls
- Constipation affects 20-40% of pregnant women and is caused by progesterone-mediated slowing of GI motility 1
- Hemorrhoids occur in approximately 80% of pregnant women, most commonly in the third trimester due to compression by the gravid uterus 1
- Always ensure adequate hydration when increasing fiber intake to prevent worsening constipation
- Detailed history is essential: Ask about bowel movement frequency, stool consistency, pain, bleeding, and symptom severity to guide treatment intensity
Evidence Strength
The recommendations are based on the 2024 AGA Clinical Practice Update on Pregnancy-Related GI and Liver Disease 1, the highest quality and most recent guideline available. This is supplemented by the 2023 AGA-ACG guideline on chronic constipation 4, which provides specific dosing for osmotic laxatives and notes lactulose as the only osmotic agent studied in pregnancy. Recent RCTs 2, 3 provide additional comparative effectiveness data between PEG and lactulose.